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European survey on knowledge and attitudes 
of public health professionals on public 
health genomics: pilot study
ABSTRACT 
Background: During the past decade a debate has arisen on the possible utility of genomic science for public health 
purposes. Within this context, a survey is being conducted to assess attitudes of European public health (PH) professionals 
belonging to European Public Health Association (EUPHA)  network regarding their role in the implementation of public 
health genomics (PHG), and their knowledge and attitudes regarding genetic testing and the delivery of genetic services. 
Methods: A pilot on-line survey was conducted on professionals from Sapienza University of Rome and the Vrije 
University of Amsterdam. The survey tool is composed of 5 sections: Personal details, Professional activity, Knowledge 
on genetic testing and delivery of genetic services, Attitudes on genetic testing and delivery of genetic services, 
Attitudes on the role of PH professionals in PHG. 
Results: 34 people responded to the questionnaire, mostly medical doctors (61.8%). No respondents correctly identified all 
evidence-based applications of genetic testing. More than one third of respondents agreed that it would be more important 
to invest resources in the social and environmental causes of ill health than in genetic testing. Nearly 70% thought that PHG 
needs to be grounded on evidence of effectiveness, a lower rate agreed ii should be grounded on cost-effectiveness. The 
rate of agreement with the proposed roles of PH professionals in PHG was very high. 
Conclusion: This pilot study showed a positive attitude but the need to improve knowledge of PH professionals on 
PHG. It provided useful input for the implementation of the survey to all members of the EUPHA network
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INTRODUCTION
Over the last decade, further to the continuous 
development of genomic applications for use in clinical 
practice, several surveys have been conducted to 
evaluate knowledge, attitudes and professional behaviors 
of physicians on this topic, identifying gaps in their 
knowledge and in the capacity to incorporate these new 
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technologies into practice. [1-6] Only one study has so 
far addressed knowledge and attitudes of public health 
professionals on genomic applications, showing that 
while they have the necessary attitudinal background to 
contribute to the proper use of predictive genetic testing 
for chronic diseases, there is the need to increase their 
methodological knowledge in this field. [7]
Public health professionals may play different roles in 
the translation of genomics research into health benefits for 
individuals and populations: they may act as the “honest 
brokers” responsible for evaluating the effectiveness of 
genomic applications; they may use genomics tools to 
evaluate the health impact of public health interventions 
on different subsets of the population; most importantly, 
public health professionals can contribute to modelling and 
evaluating the implementation of evidence based genomic 
applications. [8] Assessing and developing their capacity in 
this field is therefore a crucial element for the incorporation of 
genomics into public health (Public Health Genomics-PHG).
In view of fostering the integration of PHG into public 
health practice in Europe, a survey will be conducted on a 
sample of European public health professionals belonging 
to the network of the European Public Health Association 
(EUPHA) to assess their knowledge and attitudes regarding 
PHG. The survey will be conducted within the project 
“Personalized pREvention of Chronic DIseases consortium 
(PRECeDI)”, funded by the EU program Marie Skłodowska-
Curie Research and Innovation Staff Exchange (RISE). The 
aim of this paper is to describe the pilot phase of the survey 
conducted with the aim to assess to ensure practicability, 
validity of the survey questionnaire and interpretation of 
answers.
METHODS
A specific questionnaire was developed to assess 
knowledge and attitudes of European public health 
professionals on PHG, consisting of 33 items grouped 
into five sections: A. Professional details (4 questions); 
B. Professional activity (7 questions); C. Knowledge 
on genetic testing and delivery of genetic services (8 
questions); D. Attitudes on genetic testing and delivery of 
genetic services (8 questions); E. Attitudes on the role of 
public health professionals in PHG (6 questions). A first 
draft of the questionnaire was shared with the participants 
in the Round Table organized by the EUPHA Section 
on PHG at the 8th European Public Health Conference 
(Milan, 14-17 October 2015), who were contacted via 
e-mail in April 2016 to access a first draft of the on-line 
survey, and with all PRECeDI project partners. Following 
this first consultation, which lead to some rephrasing to 
improve the clarity of some questions, it was decided to 
create a filter question that would give access to a reduced 
version of the questionnaire for some professional groups 
not involved in genomics. It was assumed, in fact, that 
EUPHA network members belong to one of the following 
categories: public health (PH) professionals involved in 
PHG activities; PH professionals not involved in PHG; not 
PH professionals involved in PHG (e.g. geneticists); not PH 
professionals not involved in PHG (e.g. infectious diseases 
specialists). The filter question directed respondents not 
directly involved in PHG activities to a reduced version of 
the questionnaire, including only four items in both sections 
C and D (see supplement).
A link to the final version of the self-administered 
anonymous online questionnaire (see supplement) was 
e-mailed to 61 staff members from the Department of Public 
Health and Infectious Diseases of Sapienza University and 
10 members from the Department of Genetics from the 
Vrije University in Amsterdam. Staff members from different 
backgrounds were selected with the aim to guarantee 
the representativeness of the different profiles of EUPHA 
network members as outlined above. An information letter 
with details of the study, including its purpose and an 
TABLE 1. Socio-demographic characteristics of respondents
CHARACTERISTICS N (%)
Gender
Female
Male
26 (76.5)
8 (23.5)
Age
≤35
36-45
>45
10(29.4)
7 (20.6)
17 (50.0)  
Personal/family history of genetic 
disorder/hereditary syndrome
Yes 
No
5 (14.7)
29 (85.3)
Type of health professional
PH professional not involved in PHG
PH professional involved in PHG
Not PH professional not involved in PHG
Not PH professional involved in PHG
16 (47.1)
6 (17.7)
9 (26.5)
3 (8.7)
Highest academic degree
Bachelor
Master’s
Doctorate
Specialization
10 (29.3) 
3 (8.9)
17(50.0)
4 (11.8)      
Area of degree
Medicine
Biology
Other (mathematics=1, chemistry=1, 
epidemiology=1)
21 (61.7)
10 (29.4)
3 (8.9)
Sector of work 
Academic
Hospital
Public health service
28 (82.4)
5 (14.7)
1(2.9)  
Information on genetic screening in 
undergraduate training
Yes
No
20 (58.8)
14 (41.2)
Information on genetic screening in 
postgraduate training
Yes
No
Not applicable
21 (61.8)
11 (32.3)
2 (5.9)
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internet link for the survey, was sent to the participants by 
email. A reminder email was sent two weeks later. 
Attitudes on the role of PH professionals in the 
implementation of PHG and on genetic testing and 
delivery of genetic services were assessed through a 
five-point Likert scale ("strongly agree", "agree", neither 
agree nor disagree", "disagree", "strongly disagree"), 
while knowledge was assessed through closed answers 
questions, some of which allowed multiple answers. 
Statistical analysis was performed with Stata version 12.0 
software (Stata Corporation, College Station, TX, USA) 
using, for this pilot phase, descriptive analysis (frequencies, 
percentages, mean values, SD). Cronbach alpha score 
was calculated for questions belonging to the last section 
“Attitudes regarding the roles of public health professionals 
in PHG”, in order to measure its internal consistency. All 
data were processed anonymously. 
RESULTS
Thirty-four participants (response rate: 47.9%) 
completed the survey after the reminder. The age of the 
respondents ranged from 28 to 64 years (mean age: 
43.4 years±9.8), 76.5% were female (Table 1). Nearly 
a half of respondents (47%) were PH professionals not 
involved in PHG, 61.8% of them were medical doctors, 
82.4% worked in the academic sector and 14.7% in 
a hospital (Table 1). PHG represented one of the main 
areas of work for 11.8% of the sample (data not shown). 
Nine respondents (26.5%) had access to the whole set of 
questions, while 25 (73.5%) accessed the 25-items version 
of the questionnaire.  
With regards to knowledge, no respondent could 
correctly identify all applications that are currently based 
on an evidence of effectiveness (based on the definition 
of genetic testing provided by the National Human 
Genome Research Institute-National Institutes of Health, 
USA) [9]. The rate of correct answers was higher among 
professionals involved in PHG (55%.6 correctly identified 
at least seven applications vs 24.0% among not PHG 
professionals). Similarly, a higher rate of professionals 
working in PHG correctly identified all clinical conditions 
for which there is (and there is not) evidence supporting the 
implementation of genetic testing compared to those not 
involved in genomics’ activities (55.6% vs 8.0%). 
In terms of attitudes, more than one third of respondents 
agreed that it would be more important to invest resources 
in the social and environmental causes of ill health than in 
implementing genetic testing. The rate of agreement with 
this statement was lower among professionals involved 
in PHG activities (55.6% vs 84.0%). Nearly 70% 
of respondents thought that genetic testing should be 
introduced in clinical practice only with evidence of 
efficacy (all professionals working in PHG strongly agreed 
with this statement), while a lower rate of respondents 
thought that it should necessarily be grounded on cost-
effectiveness, also among professionals working in PHG 
(55.6% vs 60.0% in not PHG professionals). 
Finally, attitudes regarding the tole of PH professionals 
in the actual integration of genomics into public health 
activities were very positive (Table 2). There was no clear 
disagreement with any of the statements included in the 
questionnaires, with a few exceptions regarding the issue 
that “public health thinking should consider that risk factors 
can affect subsets of the population differently based 
on genetic susceptibility” (Table 2). With regards to this 
dimension, it was also possible to calculate Cronbach’s 
TABLE 2. Attitudes of respondents on the role of PH professionals in PHG, N (%)
Statement Strongly 
agree
Agree Neither
agree nor 
disagree
Disagree Strongly 
disagree
Public health thinking should consider that risk factors 
can affect subsets of the population differently based 
on genetic susceptibility.
10(32.3) 19(61.3) 0 1(3.2) 1(3.2)
Public health professionals should be involved in the 
continuous assessment of the utility and validity of 
emerging genomic applications
11(35.5) 19 (61.3) 1(3.2) 0 0
Public health programs should actively implement 
genomic applications that are evidence-based (e.g. 
BRCA testing for relatives of known mutation carriers).
12(38.7) 16(51.6) 3(9.7) 0 0
Public health professionals should measure the 
utilization of genetic services in order to assess unmet 
needs and inequalities of access to services
9(29.0) 18(58.1) 4(12.9) 0 0
Public health professionals should measure in practice 
outcomes, process indicators and value added of 
genomic applications
8(25.8) 21(67.7) 2(6.5) 0 0
I think that in the future public health programmes 
(e.g. cancer screening, chronic diseases prevention 
programmes) will make a stronger use of genetic 
information.
10(32.3) 19(61.3) 2(6.4) 0 0
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alpha, which resulted in a value of 0.77, showing a 
good level of internal consistency in the section of the 
questionnaire assessing attitudes regarding the role of PH 
professionals in PHG.
DISCUSSION
The sample of this pilot study showed a very 
positive attitude towards PHG, but the need to improve 
knowledge on the appropriateness of genetic testing and 
on delivery models of genetic services. Some deficiencies 
in knowledge were also found among professionals 
involved in PHG activities. These preliminary results are 
consistent with the findings of the study conducted on 
the members of the Italian Society of Hygiene, Preventive 
Medicine and Public Health (S.It.I.), [3] which indicated 
the need for additional training on genomic for public 
health professionals in Italy. However, it must be noted that 
a quite high proportion of respondents to this pilot phase 
were not PH professionals not involved in PH activities 
(26.5%): we expect the rate of respondents belonging to 
this group to be much lower in the final survey conducted 
on the EUPHA network - since it is mainly composed of 
European national PH society members who will fall in 
one of the two groups of PH professionals, probably also 
changing the trend of response rates provided.
The small sample size did not allow an analysis of 
the determinants of attitudes and knowledge, which was, 
however, beyond the scope of this pilot study, being 
investigated once the survey addressed to all members of 
the EUPHA network will be completed. Also, differences 
in response rates between the two groups of PHG and 
not PHG professionals should be interpreted with caution, 
given the small number of respondents, in particular PHG 
professionals.
The pilot study was successful in testing the clarity and 
structure of the questionnaire, with some of the comments 
provided used to improve the formulation of questions, and 
internal consistency of one of its sections. It was not possible 
to measure internal consistency on section D, since the 
different items included address a very heterogeneous group 
of issues, ranging from attitudes towards evidence based 
medicine to attitudes towards the organizational models for 
a genetic service. The final survey was launched in February 
2017 and is currently ongoing. 
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